Editor's take: Microsoft is doubling down on its plan to turn Windows 11 into an "agentic AI" platform, and in the process seems determined to strip away the last bits of user agency left in the OS.

There are lots of things that have gone viral, for all sorts of different reasons. The latest viral craze struck after a developer released a tool to strip Windows of its AI capabilities, and X is ...

LONDON — When Zohran Mamdani swept to a historic win in New York City's mayoral race, it made headlines well beyond the city and the United States. Newspapers across Europe ran analyses and ...

The internet makes connecting with old friends and acquaintances easier than ever, but it also exposes personal information to advertisers, scammers and potential criminals. Hundreds of websites have ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

There is perhaps nothing that has plagued the electronics consumer quite as much as bloatware. It’s omnipresent in most modern operating systems and products, whether it’s extra stuff on Android ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Times Watchdog stories dig deep to hold power accountable, right wrongs and create change. This work is made possible by The Seattle Times Investigative Journalism Fund. Donate today to support ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

We recently published 10 Big Names With Explosive Growth. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals jumped by 16.44 percent on ...

Whenever I give an interview about scientific research on left-handedness, at one point or another, the interviewer will ask the question of what things left-handers have an advantage in over ...